BioCentury

.@US_FDA has at least 11 PDUFA dates in August: a BioCentury Data Byte. At least two of the assets had already encountered setbacks buff.ly/n13y393

An HTT variant increases the risk of fibromyalgia, engineered bacteria deliver immunotherapies to solid tumors, and more in BioCentury’s Science Spotlight. buff.ly/Zoi4Hrv

A reverse merger and $287M PIPE will bring Caldera to the public markets, forging a quick path from NewCo to NASDAQ for the IBD company buff.ly/zpQAwxG

Biotechs entering the ranks of billion-plus buyers. Mid- to large-cap biotechs are making up a growing share of $1B+ takeouts. buff.ly/VKopWf6

Promise builds for the B7-H3 target in underserved cancers with news that Hansoh's GSK-partnered risvutatug rezetecan extended progression-free survival for osteosarcoma patients buff.ly/yUzewZ7

FDA pulls in melanoma, trial design, radiology experts for Replimune adcomm that will assess stark differences btwn agency and company. buff.ly/DwlafEc

BioCentury's latest biopharma management moves: CEOs departing Legend, Sarepta buff.ly/EChiThc

#BioCenturyThisWeek podcast: Argenx's $2.2B takeout of Forte, mapping AI giants' moves in biopharma, and 1H26 clinical wins and losses $NVDA $GOOG $AMZN $ARGX $FBRX buff.ly/Ym6KFCk

SPAC, reverse merger take Oak Hill, Scancell to NASDAQ. BioCentury's Deals Report, July 21-27 buff.ly/wpES9SW

Maplight falls as once-daily arm of Cobenfy rival misses in schizophrenia. BioCentury's Clinical Report for July 21–27 buff.ly/BYEOdQy

Argenx enters the biotech buyer class with its $2.2B Forte takeout, aiming to develop lead molecule FB102 across multiple immunology indications, running the same playbook that's taken $ARGX's Vyvgart to blockbuster heights buff.ly/2OR1OM4

BioCentury's latest biopharma management roundup: Song among trio of new partners at Venrock. Plus: moves at Sanofi, Biogen, Roche and more buff.ly/q9SKiuT

Hub 101: Taiwan biotech looks to level up. Four companies show how Taiwan is combining global ambition, local capital, and technology strengths to build a biotech hub buff.ly/egdUExo

EMA’s CHMP backs two orphan drugs, rebuffs FDA-approved NPC therapy. Among eight positive opinions, Minoryx’s cALD therapy wins backing after a 2024 rejection. buff.ly/CPTdaYC

In BioCentury's Public Equity Report: Scribe's upsized IPO; Freenome, Mentari draw PIPEs during reverse mergers; Dyne's follow-on; and more buff.ly/fGqC81l

Mapping AI giants’ bets across the biopharma tech stack. BioCentury looks at where Anthropic, NVIDIA, Google, OpenAI and Amazon’s recent life science releases fit within biopharma R&D workflows, and with each other. buff.ly/U6n06TX

BioCentury's latest Science Spotlight includes several host-directed antiviral papers from China and a Stanford-MD Anderson bivalent molecular glue collab with Deep Origin buff.ly/J2CEUgq

In BioCentury's Venture Report: Crossovers join Crystalys' $130m series B to drive gout treatment's development; Iceland-based Synaptiq spins out; Dimension's new fund; and more buff.ly/VVIcRZQ

Dosing, liver profile may differentiate Arrowhead in severe hypertriglyceridemia. Phase III data suggest little differentiation in efficacy versus Ionis’ Tryngolza, but Redemplo could offer advantages in dosing and hepatic safety buff.ly/RSzIBjt

Initiate’s Owens on early funding and what it takes to be AI-native. On The BioCentury Show, founding Partner Jessica Owens details firm’s strategy, how proprietary data beats proprietary models, and gaps in evidence generation buff.ly/HwLBrhT